COVID-19 SARS-CoV-2 Screening Protocol

Covid19 Clinical Trial

Official title: Screening Protocol for a Dose Finding Human Experimental Infection Study in Healthy Subjects Using a GMP-produced SARS-COV-2 Wild Type Strain

Status Completed

Clinical Trial Summary

The aim of this screening protocol is to assess volunteers for their potential eligibility to participate in a dose finding human experimental infection study in healthy subjects using a GMP-produced SARS-CoV-2 wild type strain

Clinical Trial Description

Recruitment will be done through a number of channels:

• Approved advertising, including social medial

• hVIVO volunteer database

• Referral

• Organic search, i.e. where the volunteer has learned of this study by doing a Google search or through friends or family rather than due to any advertising Following Research Ethics Committee approval of the full study, screened subjects who confirm their willingness to participate in the SARS-CoV-2 human infection challenge characterization study will be invited to consider the study-specific PIS-ICF and enter the final study consenting process.

The number of subjects who are to be recruited will depend on specific sample-size requirements for the SARS-CoV-2 human infection characterization study. ;

Related Conditions & MeSH terms

• Covid19

• NCT number: NCT04740320
• Study type: Observational [Patient Registry]
• Source: Imperial College London
• Status: Completed
• Start date: December 15, 2020
• Completion date: July 9, 2021